Jazz Pharmaceuticals (NASDAQ:JAZZ) Earns Buy Rating from Barclays

Barclays reaffirmed their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research report report published on Thursday morning, AnalystRatings.com reports. The brokerage currently has a $182.00 price objective on the specialty pharmaceutical company’s stock.

Several other research analysts have also issued reports on JAZZ. Evercore ISI reiterated a buy rating on shares of Jazz Pharmaceuticals in a report on Monday, August 12th. Piper Jaffray Companies lowered Jazz Pharmaceuticals from an overweight rating to a neutral rating and cut their price target for the stock from $205.00 to $142.00 in a report on Wednesday, August 21st. Wells Fargo & Co reiterated a buy rating on shares of Jazz Pharmaceuticals in a report on Wednesday, August 14th. TheStreet lowered Jazz Pharmaceuticals from a b- rating to a c+ rating in a report on Friday, October 18th. Finally, BidaskClub lowered Jazz Pharmaceuticals from a sell rating to a strong sell rating in a report on Friday, October 11th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $165.71.

JAZZ traded up $4.18 on Thursday, reaching $130.14. The stock had a trading volume of 747,500 shares, compared to its average volume of 551,936. The firm has a 50-day moving average of $124.77 and a 200-day moving average of $131.70. The company has a market capitalization of $7.24 billion, a price-to-earnings ratio of 10.63, a price-to-earnings-growth ratio of 1.57 and a beta of 1.09. The company has a current ratio of 3.71, a quick ratio of 3.52 and a debt-to-equity ratio of 0.58. Jazz Pharmaceuticals has a fifty-two week low of $113.52 and a fifty-two week high of $154.44.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.19 by $0.91. The business had revenue of $537.70 million for the quarter, compared to analyst estimates of $523.92 million. Jazz Pharmaceuticals had a return on equity of 28.57% and a net margin of 29.61%. The company’s quarterly revenue was up 14.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.58 earnings per share. Sell-side analysts anticipate that Jazz Pharmaceuticals will post 13.54 EPS for the current fiscal year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

In other news, SVP Paul Treacy sold 4,371 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $137.40, for a total value of $600,575.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $130.00, for a total value of $65,000.00. Following the completion of the transaction, the chief executive officer now owns 311,855 shares in the company, valued at approximately $40,541,150. The disclosure for this sale can be found here. Insiders sold 5,371 shares of company stock worth $730,575 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Several hedge funds have recently bought and sold shares of JAZZ. Renaissance Technologies LLC increased its position in shares of Jazz Pharmaceuticals by 28.2% during the second quarter. Renaissance Technologies LLC now owns 2,555,801 shares of the specialty pharmaceutical company’s stock valued at $364,355,000 after acquiring an additional 562,700 shares during the last quarter. Nuveen Asset Management LLC increased its position in shares of Jazz Pharmaceuticals by 4,979.1% during the second quarter. Nuveen Asset Management LLC now owns 1,924,270 shares of the specialty pharmaceutical company’s stock valued at $274,324,000 after acquiring an additional 1,886,384 shares during the last quarter. Boston Partners increased its position in shares of Jazz Pharmaceuticals by 2.7% during the second quarter. Boston Partners now owns 1,341,023 shares of the specialty pharmaceutical company’s stock valued at $191,116,000 after acquiring an additional 35,360 shares during the last quarter. LSV Asset Management increased its position in shares of Jazz Pharmaceuticals by 12.5% during the second quarter. LSV Asset Management now owns 1,127,120 shares of the specialty pharmaceutical company’s stock valued at $160,682,000 after acquiring an additional 125,470 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in shares of Jazz Pharmaceuticals by 46.9% during the second quarter. AQR Capital Management LLC now owns 1,057,019 shares of the specialty pharmaceutical company’s stock valued at $147,496,000 after acquiring an additional 337,396 shares during the last quarter. Institutional investors own 87.71% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Article: What is a stock split?

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Leave a Reply

Your email address will not be published. Required fields are marked *

*